Beck E J, Tolley K, Power A, Mandalia S, Rutter P, Izumi J, Beecham J, Gray A, Barlow D, Easterbrook P, Fisher M, Innes J, Kinghorn G, Mandel B, Pozniak A, Tang A, Tomlinson D, Williams I
Department of Epidemiology and Public Health, NPMS Coordinating and Analytic Centre, Imperial College School of Medicine, London, England.
Pharmacoeconomics. 1998 Dec;14(6):639-52. doi: 10.2165/00019053-199814060-00005.
The aim of the study was to measure the use and estimate the cost of HIV service provision in England.
Standardised activity and case-severity data were collected prospectively in 10 English HIV clinics (5 London and 5 non-London sites) for the periods 1 January 1996 to 30 June 1996 and 1 July 1996 to 31 December 1996 and linked to unit cost data. In total, 5440 patients with HIV infection attended during the first 6 months and 5708 during the second 6 months in 1996.
The mean number of inpatient days per patient-year for patients with AIDS was 19.7 [95% confidence interval (CI): 13.7 to 25.7] for January to June and 20.8 (95% CI: 15.3 to 26.4) for July to December 1996. The mean number of outpatient visits for asymptomatic patients with HIV infection was 14.8 (95% CI: 11.9 to 17.6) and 13.3 (95% CI: 10.8 to 15.7) for the respective periods and 16.1 (95% CI: 13.21 to 18.97) and 15.7 (95% CI: 11.2 to 20.2), respectively, for patients with symptomatic non-AIDS (i.e. symptomatic patients with HIV infection but without AIDS-defining conditions). Substantial centre-to-centre variation was observed, suggesting that many clinics can continue the shift from an inpatient- to an outpatient-based service. Cost estimates per patient-year for HIV service provision for 1996 varied from 4695 Pounds (95% CI: 3769 Pounds to 5648 Pounds) for asymptomatic patients, to 7605 Pounds (95% CI: 6273 Pounds to 8909 Pounds) for symptomatic non-AIDS patients to 20,358 Pounds (95% CI: 17,681 Pounds to 23,206 Pounds) for patients with AIDS.
Different combinations of antiretroviral therapy affect the cost estimates of HIV service provision differently. Anticipated reduction in inpatient-related activity through the increased use of combination antiretroviral therapy will further shift service provision from an inpatient- to outpatient-based service and reduce costs per patient-year. The extent and duration of such effects are currently unknown. The long term effects of combination treatment on the morbidity and mortality patterns of individuals infected with HIV are also currently unknown, as are their implications on the use and cost of HIV service provision. Multicentre databases like the National Prospective Monitoring System (NPMS) will provide healthcare professionals with information to improve existing services and anticipate the impact of new developments.
本研究旨在衡量英格兰艾滋病病毒(HIV)服务的使用情况并估算其成本。
前瞻性收集了1996年1月1日至1996年6月30日以及1996年7月1日至1996年12月31日期间,英格兰10家HIV诊所(5家位于伦敦,5家位于非伦敦地区)的标准化活动和病例严重程度数据,并将其与单位成本数据相联系。1996年,前6个月共有5440例HIV感染患者就诊,后6个月有5708例。
1996年1月至6月,艾滋病患者的人均住院天数为19.7天[95%置信区间(CI):13.7至25.7天],7月至12月为20.8天(95%CI:15.3至26.4天)。无症状HIV感染患者的人均门诊就诊次数在相应时期分别为14.8次(95%CI:11.9至17.6次)和13.3次(95%CI:10.8至15.7次),有症状的非艾滋病患者(即有HIV感染症状但无艾滋病界定条件的患者)分别为16.1次(95%CI:13.21至18.97次)和15.7次(95%CI:11.2至20.2次)。各中心之间存在显著差异,这表明许多诊所可以继续从住院服务为主向门诊服务为主转变。1996年,为HIV感染者提供服务的人均年成本估计,无症状患者为4695英镑(95%CI:3769英镑至5648英镑),有症状的非艾滋病患者为7605英镑(95%CI:6273英镑至8909英镑),艾滋病患者为20358英镑(95%CI:17681英镑至23206英镑)。
不同的抗逆转录病毒疗法组合对HIV服务成本估计的影响不同。预计通过增加使用联合抗逆转录病毒疗法,与住院相关的活动将减少,这将进一步使服务提供从住院为主转向门诊为主,并降低人均年成本。目前尚不清楚这些影响的程度和持续时间。联合治疗对HIV感染者发病率和死亡率模式的长期影响目前也不清楚,其对HIV服务使用和成本的影响同样未知。像国家前瞻性监测系统(NPMS)这样的多中心数据库将为医疗保健专业人员提供信息,以改善现有服务并预测新进展的影响。